Opdivo (nivolumab – BMS) and Cometriq (cabozantinib -Exelixis) demonstrated positive results in studies of patients with kidney cancer. Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more than 100,000 deaths annually. Globally, the five-year survival rate for those diagnosed with metastatic, or advanced kidney cancer, is 12.1 percent. Continue reading
Cancers are tumors that cross the basement membrane and develop invasiveness, the ability to intravasate into blood vessels, and then to colonize and grow at distant sites. Complex heterotypic cellular interactions inside the tumor are responsible for this.
Researchers examined large-scale genomic datasets and found that patients with higher levels of miR-182 had a better chance of surviving glioblastoma (GBM) longer. This prompted them to perform pre-clinical studies to elucidate the mechanism by which miR-182 acts. Continue reading
Cellular migration, a normal process in development that is lost in adulthood, is essential for cancer cells to become metastatic, thereby deadly. Continue reading
Bavituximab is a monoclonal antibody that binds to phosphatidyl serine (PS), a molecule this is expressed in the inner side of the cell membrane. The drug is being developed by Peregrine Pharmaceuticals for the treatment of non-small cell lung cancer and is in a late stage trial called SUNRISE – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer. Continue reading
Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading
The Chop protein, not to be confused with the CHOP chemotherapy regimen for lymphoma (Cyclophosphamide, Hydro doxorubicin – Adriamycin, Oncovin – vincristine, and Prednisone), is a multifunctional transcription factor. This 29 kda protein that is produced following unfolded protein stress in the endoplasmic reticulum, which then triggers apoptosis. Continue reading